Archives
Vascular Effects of JAK Inhibitors on Endothelial Cells in I
2026-08-03
Vascular Effects of JAK Inhibitors on Endothelial Cells in Inflammatory Contexts
Study Background and Research Question
Chronic systemic inflammation, particularly in autoimmune diseases such as rheumatoid arthritis (RA), is closely linked to increased cardiovascular (CV) risk. Endothelial cell (EC) dysfunction, driven by the synergistic action of pro-inflammatory cytokines like tumor necrosis factor (TNF) and interleukin-17A (IL-17A), plays a central role in promoting thrombosis and vascular complications. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key mediator of cytokine signaling, and small-molecule JAK inhibitors (JAKi) are now widely used in immune regulation and inflammatory disorder research. However, recent clinical alerts about potential CV risks associated with JAKi have driven the need for comparative mechanistic studies to clarify how different JAK inhibitors affect EC function under inflammatory stress.The reference study by Zavoriti and Miossec investigates the similarities and differences in vascular responses to various approved JAK inhibitors—including tofacitinib citrate (CP-690550 citrate), baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib—when human ECs are exposed to TNF and IL-17A (ACR Open Rheumatology, 2025). This work addresses an urgent translational question: How do specific JAK inhibitors modulate inflammatory, procoagulant, and apoptotic responses in ECs, and what are the implications for cardiovascular safety in inflammatory disease models?
Key Innovation from the Reference Study
The innovation of the Zavoriti and Miossec study lies in its direct, side-by-side evaluation of multiple clinically relevant JAKi under identical, cytokine-driven inflammatory conditions in vascular ECs. While prior research has catalogued the immunomodulatory actions of JAK inhibitors, this work uniquely dissects each compound’s impact on a spectrum of vascular endpoints—including cytokine secretion (IL-6, IL-8), adhesion molecule expression (VCAM-1, ICAM-1, E-selectin), procoagulant factor induction (tissue factor), anticoagulant downregulation (thrombomodulin), and rates of EC apoptosis. The inclusion of both low (1 μM) and high (10 μM) concentrations enables detection of dose-dependent and molecule-specific effects, which is critical for translational relevance and protocol design.Methods and Experimental Design Insights
Human vascular ECs were subjected to massive inflammatory stress via combined TNF and IL-17A stimulation, mimicking the cytokine milieu pertinent to RA and related disorders. Each JAK inhibitor—covering a range of selectivity profiles from pan-JAK (peficitinib) to more selective agents (tofacitinib citrate as a JAK3-preferential inhibitor)—was applied at 1 or 10 μM. The study measured:- IL-6 and IL-8 secretion by enzyme-linked immunosorbent assay (ELISA), capturing key inflammatory outputs.
- Gene expression of adhesion molecules (VCAM-1, ICAM-1, E-selectin) and coagulation/fibrinolysis factors by quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR).
- Endothelial apoptosis using Annexin V staining, probing cytotoxicity and cell death.
Core Findings and Why They Matter
The study’s findings clarify the vascular pharmacology of JAK inhibitors under inflammatory duress:- All tested JAKi, including tofacitinib citrate, reduced IL-6 release in ECs exposed to TNF+IL-17A, confirming their anti-inflammatory potential.
- Suppression of IL-8 was more selective: only baricitinib and fedratinib significantly decreased IL-8 overproduction at 1 μM.
- Adhesion molecule modulation was compound- and dose-dependent. Tofacitinib citrate specifically reduced ICAM-1 and E-selectin induction at 1 μM but did not prevent upregulation at higher doses (10 μM), where most JAKi paradoxically enhanced VCAM-1 and ICAM-1 expression in the inflammatory setting.
- Procoagulant responses (tissue factor upregulation) were mitigated mainly by peficitinib and fedratinib at both tested concentrations, while ruxolitinib was effective only at 1 μM. None of the inhibitors prevented the loss of thrombomodulin, a key anticoagulant.
- Peficitinib and fedratinib induced pronounced EC apoptosis and cytotoxicity, whereas tofacitinib and other JAKi did not exhibit strong pro-apoptotic effects at the concentrations tested.
Comparison with Existing Internal Articles
Recent internal resources corroborate and extend these findings. For example, the article "Distinct Vascular Effects of JAK Inhibitors in Inflammatory Stress" (link) provides a comparative overview of JAKi actions on ECs, aligning with the reference study in showing that tofacitinib citrate and related compounds display both anti-inflammatory activity and nuanced, sometimes countervailing, effects on adhesion molecules and procoagulant pathways. Similarly, "Tofacitinib Citrate in Translational Immunology" (link) bridges basic mechanistic insights with practical protocol guidance, highlighting cardiovascular safety considerations and workflow optimizations for immune regulation research.The protocol-focused guide, "Tofacitinib Citrate (CP-690550): Protocols for JAK3 Research" (link), emphasizes the importance of nanomolar precision and careful dose titration—echoing the reference study’s demonstration of dose-dependent vascular effects. These articles collectively advocate for integrative protocol design, informed by both anti-inflammatory and procoagulant endpoints, when deploying JAK inhibitors in endothelial or immune cell models.
Limitations and Transferability
While the study robustly compares JAKi in a controlled in vitro setting, several limitations temper direct extrapolation to in vivo or clinical contexts. First, the cytokine-driven model, while relevant for RA and vascular inflammation, does not capture the full complexity of systemic immune signaling, nor the pharmacokinetics/dynamics encountered in patients. Notably, TNF and IL-17A do not directly signal through the JAK-STAT pathway, so observed effects may partly reflect indirect network interactions (reference study). Furthermore, the pro-apoptotic and cytotoxic findings—especially for peficitinib and fedratinib—highlight the necessity of careful reagent selection and concentration control in experimental design. Researchers should also consider that none of the tested JAKi prevented the downregulation of thrombomodulin, suggesting a persistent procoagulant risk under severe inflammatory stress.Protocol Parameters
- JAK inhibitor dosing: 1–10 μM as modeled in the study; nanomolar (10–100 nM) concentrations are typical for primary immune cell protocols according to current product information and protocol guides.
- Inflammatory challenge: TNF (10 ng/mL) + IL-17A (10 ng/mL) for 24 hours to model synergistic EC activation.
- Key readouts: ELISA for IL-6/IL-8, qRT-PCR for VCAM-1/ICAM-1/E-selectin/tissue factor/thrombomodulin, Annexin V staining for apoptosis.
- Workflow suggestion: Titrate JAKi concentrations in pilot experiments, monitor for both anti-inflammatory and procoagulant responses, and use apoptosis/cytotoxicity assays to rule out off-target effects.